Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tetanus, diphtheria, pertussis and poliomyelitis vaccine
- Development stage
- Phase 4
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The tetanus-diphtheria-pertussis-polio vaccine is a quadrivalent combination biologic used for booster immunization against tetanus, diphtheria, pertussis, and poliomyelitis. Developed by companies such as GSK (as Boostrix IPV) and Sanofi (as Repevax), the vaccine contains reduced-antigen-content diphtheria and tetanus toxoids, acellular pertussis antigens (including pertussis toxoid, filamentous hemagglutinin, and pertactin), and inactivated poliovirus (IPV) types 1, 2, and 3. It functions by stimulating the production of specific antibodies and cellular immune responses against the toxins of Clostridium tetani and Corynebacterium diphtheriae, the surface antigens of Bordetella pertussis, and the three types of poliovirus. It is primarily indicated for adolescents and adults who have previously received a primary vaccination series to ensure continued protection against these four infectious diseases.
- Brand names
- Boostrix IPVBoostrix PolioRepevaxAdacel-Polio
- Other names
- tetanus-diphtheria-pertussis-polio vaccineTdap-IPVDTPa-IPVdiphtheria, tetanus, pertussis (acellular, component) and poliomyelitis (inactivated) vaccine (adsorbed, reduced antigen(s) content)
02
Targets
FHA (Filamentous hemagglutinin)FIM2/FIM3 (Fimbriae types 2 and 3)PRN (Pertactin)Poliovirus type 1 D-antigen capsid epitopesPoliovirus type 2 D-antigen capsid epitopesPoliovirus type 3 D-antigen capsid epitopesTT (Tetanus toxoid)
Beyond the preview
Go deeper on tetanus, diphtheria, pertussis and poliomyelitis vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tetanus, diphtheria, pertussis and poliomyelitis vaccine.